Clinuvel Pharmaceuticals Limited (ASX: CUV)
Health Care · Biotechnology · AU
AU$7.94
+0.13% today · -36.1% 1Y
Clinuvel Pharmaceuticals Limited (ASX: CUV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $279.41M and employs 16 people.
Over the last twelve months the share price has lost 36.1%, trading between 7.80 and 13.48.
Tweenvest scores Clinuvel Pharmaceuticals Limited across four factors: quality 82/100, value 85/100, growth 33/100, dividend 48/100. Its strongest factor is value.
CUV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $279.41M
- Revenue (TTM)
- $65.05M
- P/E
- 11.89
- EPS
- 0.67
- Dividend yield
- 0.63%
- Beta (5Y)
- 0.58
- 52-week high
- AU$13.48
- 52-week low
- AU$7.80
- Avg volume (3M)
- —
- Shares outstanding
- 50.43M
- Employees
- 16
- Next earnings
- —
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
- ISIN
- AU000000CUV3
- Founded
- 1999
- Listed since
- Feb 11, 2001
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Abeona Therapeutics Inc.NasdaqCM: ABEO | $282.49M | $4.90 | -0.81% |
| Tanvex BioPharma, Inc.TWSE: 6541 | $281.36M | NT$33.95 | +14.70% |
| Rocket Pharmaceuticals, Inc.NasdaqGM: RCKT | $281.02M | $2.48 | -3.13% |
| AIM Vaccine Co., Ltd.SEHK: 6660 | $280.55M | HK$1.80 | +6.85% |
| Larimar Therapeutics, Inc.NasdaqGM: LRMR | $278.70M | $2.53 | -5.24% |
| Vanda Pharmaceuticals Inc.NasdaqGM: VNDA | $276.31M | $4.54 | -0.66% |
| Bicycle Therapeutics plcNasdaqGS: BCYC | $272.27M | $3.80 | -2.31% |
| SAB Biotherapeutics, Inc.NasdaqCM: SABS | $271.14M | $2.83 | -5.03% |
Figures last refreshed Oct 11, 2026.